Gaia Piperno
Overview
Explore the profile of Gaia Piperno including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
323
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Volpe S, Vincini M, Zaffaroni M, Gaeta A, Raimondi S, Piperno G, et al.
Cancers (Basel)
. 2025 Mar;
17(5).
PMID: 40075755
An Early-Stage Non-Small Cell Lung Cancer (ES-NSCLC) patient candidate for stereotactic body radiotherapy (SBRT) may start their treatment without a histopathological assessment, due to relevant comorbidities. The aim of this...
2.
Catania C, Proto C, Bennati C, Grisanti S, Colantonio I, Petrella F, et al.
Crit Rev Oncol Hematol
. 2025 Feb;
208:104633.
PMID: 39900317
Introduction: During the recent INTERACTION group congress held on February 16-17, 2024, in Milan, Italy, many aspects of early-stage lung cancer treatment were explored. This review delves into perioperative treatment,...
3.
Corrao G, Bergamaschi L, Eleonora Pierini V, Gaeta A, Volpe S, Pepa M, et al.
Tumori
. 2024 Jan;
110(1):34-43.
PMID: 38182553
Purpose: Hippocampal sparing whole-brain radiotherapy (HS-WBRT) showed significantly lower long-term side effects compared to standard WBRT. Aim of this study is to describe a HS-WBRT real-world monoinstitutional experience within a...
4.
Volpe S, Zaffaroni M, Piperno G, Vincini M, Zerella M, Mastroleo F, et al.
BMC Cancer
. 2023 Dec;
23(1):1236.
PMID: 38102575
Background: Currently, main treatment strategies for early-stage non-small cell lung cancer (ES-NSCLC) disease are surgery or stereotactic body radiation therapy (SBRT), with successful local control rates for both approaches. However,...
5.
Sterotactic Ablative Radiotherapy in a Multicentric Series of Oligometastatic SCLC: The SAMOS Cohort
Borghetti P, Facheris G, Ciammella P, Galaverni M, Granello L, Scotti V, et al.
Clin Lung Cancer
. 2023 Dec;
25(2):151-158.
PMID: 38052684
Aims: SCLC is the most aggressive lung cancer histology with a 5-year OS <10%. At the diagnosis, almost two-thirds of the SCLC an Extended Disease presentation. Two randomized studies (CASPIAN...
6.
Piperno G, Ferrari A, Volpe S, Cattani F, Zaffaroni M, Comi S, et al.
Crit Rev Oncol Hematol
. 2023 Sep;
191:104114.
PMID: 37683814
Aims: Aim of the present analysis was to report results of a systematic review of the literature in the setting of patients treated with hypoF PT for benign lesions of...
7.
Catania C, Filippi A, Sangalli C, Piperno G, Russano M, Greco C, et al.
Crit Rev Oncol Hematol
. 2023 Aug;
190:104108.
PMID: 37633350
Importance: After the PACIFIC trial, concurrent chemo-radiotherapy followed by consolidation therapy with durvalumab for 1 year (limited to PD-L1 tumour proportion score ≥ 1% in the EMA region) is the...
8.
Carloni G, Garibaldi C, Marvaso G, Volpe S, Zaffaroni M, Pepa M, et al.
Radiother Oncol
. 2022 Nov;
178:109424.
PMID: 36435336
Background And Purpose: Radiomics enables the mining of quantitative features from medical images. The influence of the radiomic feature extraction software on the final performance of models is still a...
9.
Volpe S, Piperno G, Colombo F, Biffi A, Comi S, Mastroleo F, et al.
Cancer Treat Rev
. 2022 Oct;
110:102464.
PMID: 36194908
Background: Hypofractionated proton beam radiotherapy (PBT) is gaining attention in early-stage non-small cell lung cancer (ES-NSCLC). However, there is a large unmet need to define indications, prescription doses and potential...
10.
Borghetti P, Imbrescia J, Volpi G, Scotti V, Aquilano M, Bruni A, et al.
Radiat Oncol
. 2022 Jul;
17(1):124.
PMID: 35842660
Background: tumor recurrence after NSCLC surgical resection is the most common cause of treatment failure that sharply reduces the patient's life expectancy. The optimal treatment strategy for loco-regional recurrences developing...